Travere Therapeutics, Inc. (TVTX) Monday said it has submitted supplemental New Drug Application (sNDA) to the Food and Drug Administration (FDA) seeking full approval of Filspari for the treatment of IgA nephropathy (IgAN), a chronic kidney disease.
In February last year, the FDA had granted accelerated approval to Filspari to reduce protein in the urine (proteinuria) in adults with IgAN.
Phase 3 PROTECT Study had shown that Filspari demonstrated long-term kidney function preservation and achieved a significant reduction in proteinuria versus an active comparator.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.